Therefore, the activation of signaling pathways triggered by IL-33 and IFN-α may be involved in the clinical manifestations specific to type 1 AIP and IgG4-RD, but not to SLE. This evidence concerns the gene IL33 and autoimmune pancreatitis type 1.